Naoko Takebe to Benzamides
This is a "connection" page, showing publications Naoko Takebe has written about Benzamides.
Connection Strength
0.231
-
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2025 Feb 25; 95(1):37.
Score: 0.059
-
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO Precis Oncol. 2024 Dec; 8:e2400327.
Score: 0.058
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
Score: 0.054
-
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS One. 2018; 13(6):e0199361.
Score: 0.037
-
KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34.
Score: 0.023